ATE486073T1 - 5-pyridazinyl-1-azabizycloä3.2.1üoctan-derivat, herstellungsverfahren und deren verwendung für therapeutika - Google Patents

5-pyridazinyl-1-azabizycloä3.2.1üoctan-derivat, herstellungsverfahren und deren verwendung für therapeutika

Info

Publication number
ATE486073T1
ATE486073T1 AT06794297T AT06794297T ATE486073T1 AT E486073 T1 ATE486073 T1 AT E486073T1 AT 06794297 T AT06794297 T AT 06794297T AT 06794297 T AT06794297 T AT 06794297T AT E486073 T1 ATE486073 T1 AT E486073T1
Authority
AT
Austria
Prior art keywords
pyridazinyl
therapeutics
derivative
production process
production
Prior art date
Application number
AT06794297T
Other languages
English (en)
Inventor
Frederic Galli
Odile Leclerc
Alistair Lochead
Julien Vache
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36297201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE486073(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE486073T1 publication Critical patent/ATE486073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06794297T 2005-08-18 2006-08-07 5-pyridazinyl-1-azabizycloä3.2.1üoctan-derivat, herstellungsverfahren und deren verwendung für therapeutika ATE486073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508594A FR2889847B1 (fr) 2005-08-18 2005-08-18 Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
PCT/FR2006/001911 WO2007020343A1 (fr) 2005-08-18 2006-08-07 Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE486073T1 true ATE486073T1 (de) 2010-11-15

Family

ID=36297201

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06794297T ATE486073T1 (de) 2005-08-18 2006-08-07 5-pyridazinyl-1-azabizycloä3.2.1üoctan-derivat, herstellungsverfahren und deren verwendung für therapeutika

Country Status (39)

Country Link
US (3) US7476674B2 (de)
EP (1) EP1922320B1 (de)
JP (1) JP5249758B2 (de)
KR (1) KR101260546B1 (de)
CN (2) CN101291933B (de)
AR (1) AR056461A1 (de)
AT (1) ATE486073T1 (de)
AU (1) AU2006281340B2 (de)
BR (1) BRPI0614796A2 (de)
CA (1) CA2618110C (de)
CR (1) CR9693A (de)
CY (1) CY1111101T1 (de)
DE (1) DE602006017854D1 (de)
DK (1) DK1922320T3 (de)
DO (1) DOP2006000191A (de)
EA (1) EA013601B1 (de)
EC (1) ECSP088182A (de)
ES (1) ES2354833T3 (de)
FR (1) FR2889847B1 (de)
HN (1) HN2008000276A (de)
HR (1) HRP20110043T1 (de)
IL (1) IL189014A0 (de)
JO (1) JO2680B1 (de)
MA (1) MA29913B1 (de)
MX (1) MX2008002276A (de)
MY (1) MY145923A (de)
NO (1) NO20081289L (de)
NZ (1) NZ565537A (de)
PE (1) PE20070234A1 (de)
PL (1) PL1922320T3 (de)
PT (1) PT1922320E (de)
RS (1) RS51653B (de)
SI (1) SI1922320T1 (de)
TN (1) TNSN08026A1 (de)
TW (1) TWI322808B (de)
UA (1) UA92360C2 (de)
UY (1) UY29756A1 (de)
WO (1) WO2007020343A1 (de)
ZA (1) ZA200800966B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249307B2 (en) 2011-08-16 2016-02-02 Pierce Biotechnology, Inc. Benzocyanine compounds
EP3828174A4 (de) 2018-07-19 2022-08-17 Sumitomo Pharma Co., Ltd. Pyridazinonderivat
WO2021141041A1 (ja) 2020-01-07 2021-07-15 大日本住友製薬株式会社 タウオパチーの治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
FR2786770B1 (fr) * 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
ES2223209B1 (es) 2001-12-11 2005-10-01 Esteve Quimica, S.A. Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion.
CN100398103C (zh) 2000-10-13 2008-07-02 神经研究公司 通过烟碱性受体激动剂和单胺能物质的联合作用治疗情感性精神障碍
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
US6644511B2 (en) 2002-01-11 2003-11-11 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Container for dispensing a dual phase fluid product

Also Published As

Publication number Publication date
US20090088440A1 (en) 2009-04-02
NO20081289L (no) 2008-03-17
PE20070234A1 (es) 2007-03-26
WO2007020343A1 (fr) 2007-02-22
AU2006281340B2 (en) 2012-04-12
EP1922320A1 (de) 2008-05-21
AU2006281340A1 (en) 2007-02-22
EP1922320B1 (de) 2010-10-27
MA29913B1 (fr) 2008-11-03
CA2618110C (fr) 2014-02-11
CY1111101T1 (el) 2015-06-11
JP2009504714A (ja) 2009-02-05
MY145923A (en) 2012-05-15
IL189014A0 (en) 2008-08-07
ECSP088182A (es) 2008-03-26
US8076340B2 (en) 2011-12-13
US8557819B2 (en) 2013-10-15
KR101260546B1 (ko) 2013-05-06
EA200800615A1 (ru) 2008-06-30
JP5249758B2 (ja) 2013-07-31
BRPI0614796A2 (pt) 2011-04-12
TWI322808B (en) 2010-04-01
UY29756A1 (es) 2007-03-30
HK1125628A1 (en) 2009-08-14
PL1922320T3 (pl) 2011-04-29
TNSN08026A1 (en) 2009-07-14
CN101291933A (zh) 2008-10-22
DOP2006000191A (es) 2011-11-15
DK1922320T3 (da) 2011-02-21
CA2618110A1 (fr) 2007-02-22
US20080176855A1 (en) 2008-07-24
EA013601B1 (ru) 2010-06-30
ES2354833T3 (es) 2011-03-18
US7476674B2 (en) 2009-01-13
CN102558177A (zh) 2012-07-11
ZA200800966B (en) 2009-04-29
UA92360C2 (en) 2010-10-25
PT1922320E (pt) 2011-01-19
JO2680B1 (en) 2013-03-03
AR056461A1 (es) 2007-10-10
FR2889847A1 (fr) 2007-02-23
HRP20110043T1 (hr) 2011-02-28
HN2008000276A (es) 2011-03-30
DE602006017854D1 (de) 2010-12-09
KR20080034468A (ko) 2008-04-21
TW200738715A (en) 2007-10-16
FR2889847B1 (fr) 2007-10-05
CR9693A (es) 2008-03-06
RS51653B (sr) 2011-10-31
SI1922320T1 (sl) 2011-02-28
CN101291933B (zh) 2012-03-14
MX2008002276A (es) 2008-03-27
NZ565537A (en) 2011-04-29
US20120046298A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
EP2067782A4 (de) Heteroacenderivat, tetrahalogenterphenylderivat und verfahren zu ihrer herstellung
ATE447564T1 (de) Zwischenprodukte für die herstellung von trans-5- chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzä , 3:6,7üoxepinoä4,5-cüpyrrol
EP1894626A4 (de) Homogener, hochdisperser metallkatalysator und verfahren zu seiner herstellung
PL1845978T3 (pl) Podstawione pirazolopirydyny, kompozycje je zawierające, sposób ich wytwarzania i ich zastosowanie
EP1867416A4 (de) Kantenaustauschschneidspitze und verfahren zu deren herstellung
ATE405608T1 (de) Blockförmige hydroxyethylzellulose, derivate daraus, herstellungsverfahren dafür und verwendungen davon
EP1908749A4 (de) Verfahren zur herstellung von isocyanat, danach hergestelltes isocyanat und verwendung von isocyanat
ATE492514T1 (de) Pulverförmige kalkzusammensetzung, herstellungsverfahren dafür und verwendung davon
BRPI0817186A2 (pt) "composição, método de produção de refrigeração e método de substituição"
EP1854863A4 (de) Leuchtstoff und sein herstellungsverfahren und seine verwendung
EP1873254A4 (de) Verzweigte stärke, verfahren zur herstellung davon und verwendung davon
DE602008006188D1 (de) 7-alkynyl-1,8-naphthyridon-derivate, verfahren zu ihrer herstellung und ihre verwendung für therapeutika
DE602005001930D1 (de) Derivate vom aryloxyalkylcarbamat-typ, verfahren zu deren herstellung und deren verwendung in therapeutika
EG25069A (en) Process for urea production and related plant.
DE502007001726D1 (de) Elastische Einlage, Verfahren zu deren Herstellung und Verwendung
MA28635B1 (fr) Methode de production de derives de 1, 4-diphenylazetidinone
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
DE602006000374D1 (de) Sensor für oxidierendes Gas und dessen Herstellungsverfahren
EP1870401A4 (de) 1,4-substituiertes piperazinderivat
ATE548368T1 (de) Harnstoffderivate, verfahren zu ihrer herstellung und ihre anwendungen
SE0500605L (sv) Metallprodukt, produktionsmetod och användning därav
ZA200805382B (en) Keratin-binding effector molecules, and method for the production thereof
EP1878521A4 (de) Gleitteil und verfahren zu dessen herstellung
EP1867623A4 (de) Terphenylenderivate, tetrahaloterphenylderivate und verfahren zu deren herstellung
EG25292A (en) Process for the production of anilines.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1922320

Country of ref document: EP